Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

52 results about "Angiotensin Receptor Antagonists" patented technology

Agents that antagonize ANGIOTENSIN RECEPTORS. Many drugs in this class specifically target the ANGIOTENSIN TYPE 1 RECEPTOR.

Imidazo-5-carboxylic-acid derivatives, its preparing method and use

The invention discloses an imidazole-5-carboxylic acids derivative and the manufacturing method. It is the angiotensin II acceptor antagon. It has strong angiotensin II antagonize activity and high blood pressure proofing activity. And it could be used as therapeutic agent to cure high blood pressure.
Owner:SHANGHAI ALLIST PHARM CO LTD

Novel crystalline form of angiotensin receptor antagonist and neutral endopeptidase inhibitor supramolecular complex

The present invention discloses a novel crystalline form of an angiotensin receptor antagonist and neutral endopeptidase inhibitor supramolecular complex. The novel crystalline form of the supramolecular complex has high water solubility and good stability. Experiments show that the moisture absorption and intrinsic dissolution extent and speed are superior to those of a conventional crystalline supramolecular complex.
Owner:EAST CHINA UNIV OF SCI & TECH

Composition for lowering blood pressure and application thereof

InactiveCN101890165AImprove compliancePrevent or delay damageOrganic active ingredientsMetabolism disorderTasosartanValsartan
The invention provides a pharmaceutical composition which comprises calcium channel blockers of a medicinal dose, angiotensin II receptor antagonists of a medicinal dose, one or more of B vitamins of a medicinal dose and pharmaceutically acceptable carriers, wherein the calcium channel blockers are selected from amlodipine, felodipine, israbipine, nicardipine, nifedipine, nisoldipine, nitrendipine, lacidipine, diltiazem or verapamil; the angiotensin II receptor antagonists are selected from candesartan, telmisartan, losartan, valsartan, irbesartan, eprosartan, tasosartan or olmesartan; and the B vitamins are selected from one or more of vitamin B6, vitamin B12, folic acid and calcium leucovorin. The pharmaceutical composition of the invention can improve the curative effect of the hypotensor, enhance the target organ protecting action of the hypotensor, and reduce the morbidity of complications of angina, myocardial infarction and the like.
Owner:北京奥萨医药研究中心有限公司 +1

Organic compounds

A specific combination, linked pro-drug or a compound of an angiotensin receptor antagonist and a NEPi are used in the treatment of hypertension.
Owner:NOVARTIS PHARM CORP

Novel medicine of non peptide like angiotensin II receptor antagonism agent, their preparation and application

A novel non-peptide angiotonin II receptor antagon kind of medicines, and their preparing process and application are disclosed.
Owner:BEIJING NORMAL UNIVERSITY

4,6-dihydrofuran [3,4-d] imidazole-6- ketone derivative and salt and preparation method thereof

A 4,6-dihydrofurano[3,4-d] imidazole-6-ketone derivative, its pharmacological receptible salt, and the preparing process of said derivatives are disclosed. Said compound can be used as the intermediate for synthesizing the antagon of angiotensin II receptor.
Owner:SHANGHAI INST OF PHARMA IND

Angiotensin receptor antagonist and creatine phosphate sodium complex and uses thereof

The present invention provides a an angiotensin receptor antagonist and creatine phosphate sodium complex and uses thereof, wherein the complex comprises an angiotensin receptor antagonist and creatine phosphate sodium, a molar ratio of the angiotensin receptor antagonist to the creatine phosphate sodium is 1:1-2, and the angiotensin receptor antagonist is selected from valsartan, losartan, irbesartan, telmisartan, eprosartan, candesartan, olmesartan, saprisartan, tasosartan, and elisartan. According to the present invention, the complex is formed by compounding the angiotensin receptor antagonist and the creatine phosphate sodium, and provides the unexpected double effect and the synergistic effect for treatment of heart failure and high blood pressure, the cocrystallization salt hydrate formed by linking the hydrogen bond has the stable characteristic, the pharmacokinetic property is significantly provided, and the positive application prospects are provided in the fields of anti-high blood pressure treatment and anti-heart failure treatment.
Owner:珠海赛隆药业股份有限公司(长沙)医药研发中心

Novel composing prescription sustained-release preparation for treating high blood pressure and preparation method thereof

The invention relates to a sustained release preparation of a novel prescription for treating hypertension and the preparing method thereof. The novel prescription comprises a heart selective Beta1 receptor blocker metoprolol and an angiotensin II receptor antagonist (sartan drugs). The sustained release preparation consists of delayed release part and rapid release part, wherein the heart selective Beta1 receptor blocker metoprolol is the delayed release part, with first hour releasing 25-45%, fourth hour releasing 40-75% and eighth hour releasing over 75%; the angiotensin II receptor antagonist (sartan drugs) is the rapid release part, with 45 minutes dissolution over 75%. The composition has both rapid and prolonged action. The invention discloses in vitro drug release characteristics and preparation method thereof.
Owner:BEIJING RUNDEKANG MEDICAL TECH CO LTD

Dual acting pharmaceutical compositions based on superstructures of angiotensin receptor antagonist/blocker (ARB) and ne utral endopeptidase (EP) inhibitor

Solid oral dosage forms, especially tablets, of a pharmaceutical composition comprising a supramolecular complex can be formed from a direct compression process or a compaction process such as roller compaction. Such solid oral dosage forms feature an immediate release profile that allows for fast release of the therapeutic agent. A particularly useful supramolecular complex is trisodium [3-((1S,3R)-1-biphenyl-4-ylmethyl-3-ethoxycarbonyl-1-butylcarbamoyl)propionate-(S)-3′-methyl-2′-(pentanoyl{2″-(tetrazol-5-ylate)biphenyl-4′-ylmethyl}amino)butyrate]hemipentahydrate.
Owner:NOVARTIS PHARM CORP

Angiotensin receptor antagonist and milrinone compound and use thereof

The invention provides an angiotensin receptor antagonist and milrinone compound and a use thereof. The compound comprises an angiotensin receptor antagonist and milrinone, the angiotensin receptor antagonist and milrinone can be directly mixed, or can be indirectly connected through hydrogen bonds, and cocrystallized sodium hydrate formed by using the hydrogen bonds have stable properties and substantially improved pharmacokinetic properties. The action mechanisms of the angiotensin receptor antagonist and milrinone are different, but the compound formed by the angiotensin receptor antagonist and milrinone have unexpected synergism, so the compound has positive application prospect in the anti-heart failure and anti-hypertension field.
Owner:赛隆药业集团股份有限公司(长沙)医药研发中心

1,(3,)5-substituted imidazoles, their use in the treatment of hypertension and methods for their preparation

The present invention provides novel 1,5 and 1,3,5-substituted imidazole compounds in hydrophilic or lipophilic form, which are useful as angiotensin II ATI receptor antagonists suitable for transdermal delivery. The invention also provides pharmaceutical compositions containing such compounds, processes and intermediates for preparing compounds and their use in methods of treating hypertension and cardiovascular diseases.
Owner:ELDRUG SA

Compound prepared from angiotensin receptor antagonist and enkephalinase inhibitor and application of compound

The invention provides a compound prepared from an angiotensin receptor antagonist and an enkephalinase inhibitor and application of the compound. The compound is prepared from the angiotensin receptor antagonist and the enkephalinase inhibitor, the angiotensin receptor antagonist and the enkephalinase inhibitor can be directly mixed or indirectly connected through hydrogen bonds, and a co-crystallized sodium hydrate prepared through hydrogen bond connection is more stable in property and significant in pharmacokinetic property; although the action mechanism of the angiotensin receptor antagonist and the action mechanism of the enkephalinase inhibitor are different, the compound prepared from the angiotensin receptor antagonist and the enkephalinase inhibitor has an unexpected synergistic effect and has a positive application prospect in the anti-heart-failure and anti-hypertension treatment field.
Owner:赛隆药业集团股份有限公司(长沙)医药研发中心

1,3 and 1,3,5 substituted imidazoles as antihypertensives

The present invention provides novel 1,5 and 1,3,5-substituted imidazole compounds of formulas (I), (IIa), (IIIb) in hydrophilic or lipophilic form, which are useful as angiotensin II AT1 receptor antagonists with sympathetic suppressant properties. In particular, the invention provides pharmaceutical compositions containing the pharmacophoric groups of Losartan and Clonidine as well compounds, processes and intermediates for preparing compounds and their use in methods of treating hypertension and cardiovascular diseases through Renin Angiotensin System (RAS) and Sympathetic System (SS). Alkylated histamine based double action Saltans are lipophilic and can act transdermally.
Owner:ELDRUG SA

Drug compound for AT1 receptor antagonist/diuretic/folate coupling and uses thereof

ActiveCN101199847AReduce target organ damageReduce the risk of cardiovascular and cerebrovascular eventsOrganic active ingredientsSenses disorderFolic acidPatient compliance
The invention relates to a drug combination of applying jointly angiotensin II receptor antagonist / diuretic / folacin and the purpose. The combination includes: officinal dose of angiotensin II receptor antagonist, officinal dose of diuretic, officinal does of folic acid compound and pharmacy-acceptable carrier. The invention provides the purpose of the combination in preparing the medicine used for preventing, treating or delaying hypertension, target organ damage caused by hypertension or hypertension-related diseases; the invention also provides the purpose of the drug combination in preparing the medicine used for reducing the danger of cardiovascular and cerebrovascular events caused by hypertension. The implementation of the invention, which provides the patient with the drug combination, can improve the curative effect, increase the compliance of the patient, convenience the drug administration and reduce the medical expenses.
Owner:SHENZHEN AUSA PHARMA +1

Compound of angiotensin receptor blocker and levosimendan and use of compound

The invention provides a compound of an angiotensin receptor blocker and levosimendan and use of the compound. The compound is composed of the angiotensin receptor blocker and levosimendan, which can be mixed directly or be connected indirectly through a hydrogen bond, wherein a co-crystallized sodium hydrate formed by connection through hydrogen bond is more stable in property; and the pharmacokinetic properties are improved significantly; the action mechanisms of the angiotensin receptor blocker and the levosimendan are different, but the formed compound has an unexpected synergistic effect and has positive application prospects in the anti-heart failure and anti-hypertensive treatment field.
Owner:赛隆药业集团股份有限公司(长沙)医药研发中心

Compound antihypertensive preparation and application of compound antihypertensive preparation

The invention provides a medicine composition for treating hypertension. The medicine composition is characterized in that the medicine composition comprises (1) angiotensin II receptor antagonists, (2) diuretic metolazone and (3) acceptable auxiliary materials on pharmaceutical science. The weight proportion of the angiotensin II receptor antagonists to the metolazone is 20-200:0.5-10; the angiotensin II receptor antagonists and the metolazone are combined to strengthen the collaboration antihypertensive effect; untoward effects are reduced; the compliance of patients is improved; the medication crowds are wide; and the medicine composition can be used by the patients with the seriously-damaged renal function. The medicine composition is suitable for treating mild and moderate primary hypertension, and is particularly suitable for treating secondary hypertension caused by kidney damage.
Owner:XIAN LIBANG ZHAOXIN BIOTECH CO LTD

Novel crystal form of sartan drug as well as preparation method and application thereof

The invention relates to a new crystal form of a sartan drug as well as a preparation method and application thereof, and belongs to the field of pharmaceutical chemicals. The invention discloses a sacubitril valsartan trisodium trihydrate eutectic composed of an angiotensin receptor antagonist and an enkephalinase inhibitor for treating hypertension or heart failure and a preparation method of the sacubitril valsartan trisodium trihydrate eutectic. The obtained crystal is analyzed by an X-ray powder diffraction spectrogram, and the characteristic absorption peaks 2 theta are located at 4.2 + / -0.2 degrees, 5.0 + / -0.2 degrees, 5.4 + / -0.2 degrees, 9.7 + / -0.2 degrees, 12.6 + / -0.2 degrees, 17.0 + / -0.2 degrees, 18.1 + / -0.2 degrees, 19.4 + / -0.2 degrees, 21.3 + / -0.2 degrees and 23.0 + / -0.2 degrees. The new eutectic crystal form disclosed by the invention is simple in preparation method, the crystal is easy to separate, and experiments show that the hygroscopicity and the stability of the neweutectic crystal form are superior to those of the existing eutectic crystal form, so that the new eutectic crystal form is favorable for being prepared into an oral solid preparation and processing and producing the oral solid preparation, and can be used for treating hypertension or heart failure.
Owner:GUANGZHOU BAIYUSN TIANXIN PHARMA

6-pyridin benzimidazole indole derivatives and preparation method thereof, and application of 6-pyridin benzimidazole indole derivatives in field of medicine

The invention discloses 6-pyridin benzimidazole indole derivatives and a preparation method thereof. The compounds are novel angiotensin II receptor antagonists and can be used for prevention and treatment of cardiovascular, cerebrovascular and renal-vascular diseases like hypertension, coronary heart disease and pulmonary arterial hypertension.
Owner:SHANGHAI XIANHUI MEDICAL TECH

Composition containing angiotensin II receptor antagonist, statin and folic acid as well as applications thereof

The invention relates to a pharmaceutical composition containing angiotensin II receptor antagonist, statin lipid-lowering drugs and folic acid compound. The pharmaceutical composition contains medicinal dose of angiotensin II receptor antagonist, medicinal dose of statin lipid-lowering drugs, medicinal dose of folic acid composite and a carrier acceptable in pharmaceutics. The invention also relates to an application of the pharmaceutical composition in preparing medicines for preventing and treating or retarding high blood pressure accompanied by dyslipidemia and the application thereof in preparing medicines for treating target organ damage caused by the high blood pressure accompanied by dyslipidemia; in addition, the invention further relates to the application of the pharmaceutical composition in preparing medicines for lowering risk of cardiovascular and cerebrovascular events caused by high blood pressure accompanied by dyslipidemia. The invention belongs to the pharmaceutical field. With the implementation of the invention, the pharmaceutical composition with special usage, provided to the patients, can improve compliance of the patients, bring convenience to the patients to take medicines and reduce medical expenses, thus enjoying good market prospect.
Owner:SHENZHEN AUSA PHARM CO LTD +2

Medicinal composition containing angiotensin II receptor antagonist and vitamin B

The medicine composition consists of one of AT1 receptor antagonist, its active metabolism product, ester and salt in treating effective amount of 4-800 mg, one or several kinds one B family vitamins in treating effective amount of 0.1-50 mg, and pharmaceutically acceptable carrier. The medicine composition of the present invention has the beneficial effects of raising the treating effect of blood pressure lowering AT1 receptor antagonist, strengthening the protecting effect of blood pressure lowering AT1 receptor antagonist on target organ and reducing the incidence rate of hemorrhage of the ocular fundus, angina pectoris, myocardial infarction and other complications.
Owner:SHENZHEN AUSA PHARM CO LTD +2

Novel use of complexes of metabolites of angiotensin II receptor antagonists with nep inhibitors

The invention relates to a new application of a compound of an angiotensin II receptor antagonist metabolite and an NEP inhibitor, which belongs to the technical field of pharmaceutical application, and specifically relates to the application of the compound in the preparation of medicines for salt-sensitive hypertension.
Owner:SHENZHEN SALUBRIS PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products